Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Financial Information Relating to Reportable Segments (Details)

v3.3.1.900
Note 3 - Financial Information Relating to Reportable Segments (Details) - USD ($)
 3 Months Ended 6 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Biotechnology [Member] | Operating Segments [Member]        
Net sales $ 75,854,000 $ 74,373,000 $ 151,597,000 $ 150,807,000
Operating income 39,986,000 38,038,000 79,302,000 78,465,000
Clinical Controls [Member] | Operating Segments [Member]        
Net sales 25,723,000 17,297,000 46,085,000 36,406,000
Operating income 7,297,000 5,128,000 12,010,000 11,238,000
Protein Platforms [Member] | Operating Segments [Member]        
Net sales 19,337,000 20,478,000 35,634,000 33,382,000
Operating income 1,528,000 3,447,000 356,000 6,050,000
Operating Segments [Member]        
Operating income 48,811,000 46,613,000 91,668,000 95,753,000
Intersegment Eliminations [Member]        
Net sales (7,000) (200,000) (28,000) (190,000)
Corporate, Non-Segment [Member]        
Corporate general, selling, and administrative (1,189,000) (711,000) (2,156,000) (2,007,000)
Net sales 120,907,000 111,948,000 233,288,000 220,425,000
Operating income 36,025,000 34,580,000 67,054,000 69,796,000
Costs recognized on sale of acquired inventory (1,245,000) (1,188,000) (2,357,000) (4,355,000)
Amortization expense (7,361,000) (6,858,000) (14,767,000) (12,586,000)
Acquisition related expenses (670,000) (1,201,000) (970,000) (3,571,000)
Stock based compensation (2,321,000) (2,075,000) (4,359,000) (3,437,000)
Corporate general, selling, and administrative $ (34,585,000) $ (31,137,000) $ (67,625,000) $ (59,838,000)